title: Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.
abstract: OBJECTIVE
  This study examined the effects of pioglitazone on body weight and bone mineral density (BMD) prospectively in patients with impaired glucose tolerance as pioglitazone (TZD) increases body weight and body fat in diabetic patients and increases the risk of bone fractures.
  
  
  METHODS
  A total of 71 men and 163 women aged 49.3 (10.7) years [mean (s.d.)]; body mass index (BMI), 34.5 (5.9) kg/m(2) were recruited at five sites for measurements of body composition by dual energy X-ray absorptiometry at baseline and at conversion to diabetes or study end, if they had not converted.
  
  
  RESULTS
  Mean follow-up was 33.6 months in the pioglitazone group and 32.1 months in the placebo group. Body weight increased 4.63 ± 0.60 (m ± s.e.) kg in the pioglitazone group compared to 0.98 ± 0.62 kg in the PIO group (p < 0.0001). Body fat rose 4.89 ± 0.42 kg in the pioglitazone group compared to 1.41 ± 0.44 kg, (p < 0.0001) in placebo-treated subjects. The increase in fat was greater in legs and trunk than in the arms. BMD was higher in all regions in men and significantly so in most. PIO decreased BMD significantly in the pelvis in men and women, decreased BMD in the thoracic spine and ribs of women and the lumbar spine and legs of men. Bone mineral content also decreased significantly in arms, legs, trunk and in the total body.
  
  
  CONCLUSIONS
  Pioglitazone increased peripheral fat more than truncal fat and decreased BMD in several regions of the body.
authors.affiliation: Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA.
authors.forename: G A
authors.initials: GA
authors.lastname: Bray
authors.forename: S R
authors.initials: SR
authors.lastname: Smith
authors.forename: M A
authors.initials: MA
authors.lastname: Banerji
authors.forename: D
authors.initials: D
authors.lastname: Tripathy
authors.forename: S C
authors.initials: SC
authors.lastname: Clement
authors.forename: T A
authors.initials: TA
authors.lastname: Buchanan
authors.forename: R R
authors.initials: RR
authors.lastname: Henry
authors.forename: A E
authors.initials: AE
authors.lastname: Kitabchi
authors.forename: S
authors.initials: S
authors.lastname: Mudaliar
authors.forename: N
authors.initials: N
authors.lastname: Musi
authors.forename: R E
authors.initials: RE
authors.lastname: Ratner
authors.forename: D C
authors.initials: DC
authors.lastname: Schwenke
authors.forename: F B
authors.initials: FB
authors.lastname: Stentz
authors.forename: P D
authors.initials: PD
authors.lastname: Reaven
authors.forename: R A
authors.initials: RA
authors.lastname: DeFronzo
mesh_terms: D015502:Absorptiometry, Photon; D000273:Adipose Tissue; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D050723:Fractures, Bone / Q000139:chemically induced / Q000453:epidemiology / Q000473:pathology*; D005951:Glucose Tolerance Test; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D011236:Prediabetic State / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D011446:Prospective Studies; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone
keywords: clinical trial; fat; glycaemic control